Sacha Mann
Directeur/Membre du Conseil chez Blue Mesa Health, Inc.
Profil
Sacha Mann is currently a Senior Investment Director & Partner at Takeda Ventures, Inc., a Director at Blue Mesa Health, Inc., a Director at hC Bioscience, Inc., and a Director at Larkspur Biosciences, Inc. She previously worked as an Investment Manager at Archangel Investors Ltd.
from 2007 to 2009.
Ms. Mann has a graduate degree from The Johns Hopkins University, an undergraduate degree from the University of British Columbia, and an MBA from Simon Fraser University.
Postes actifs de Sacha Mann
| Sociétés | Poste | Début |
|---|---|---|
Blue Mesa Health, Inc.
 Blue Mesa Health, Inc. BiotechnologyHealth Technology Blue Mesa Health, Inc. engages in the provision of digital therapeutics program to support the prevention diabetes and other chronic diseases. The company was founded by Misa Nuccio, Curtis Duggan, Evan Willms, Mike Benna, Jonathan Bixby, and Joshua Bixby in 2015 and is headquartered in New York, NY. | Directeur/Membre du Conseil | 01/01/2018 |
Takeda Ventures, Inc.
 Takeda Ventures, Inc. Investment ManagersFinance Takeda Ventures Inc (Takeda Ventures) is a venture capital subsidiary of Takeda America Holdings Inc founded in 2001. The firm is headquartered in Palo Alto, California. | Private Equity Investor | 01/06/2021 |
Egle Therapeutics SAS
 Egle Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Egle Therapeutics SAS is a biotech company based in Paris, France. Egle Therapeutics develops first-in-class immunotherapies targeting immune suppressor regulatory T cells (Tregs) for oncology and autoimmune diseases. The French company leverages its translational-based target discovery platform to unveil novel therapeutic Treg targets and computationally designed immunocytokines acting as antagonists or as selective Treg-agonists. The company was founded in 2020 by Luc Boblet, a serial biotech entrepreneur, and Dr. Eliane Piaggio, a renowned immunologist. | Directeur/Membre du Conseil | - |
Hc Bioscience, Inc.
 Hc Bioscience, Inc. Pharmaceuticals: MajorHealth Technology hC Bioscience, Inc. is a biotech company based in Cambridge, MA and has subsidiaries in the United States. A single trna therapy has the potential to treat many diseases, regardless of the gene or location of the mutation. hC Bioscience is dedicated to improving the lives of patients by developing first-in-class trna-based therapeutics that target protein dysfunction. The company's innovative approach to precision protein editing has the potential to treat genetically defined conditions that account for 10-15% of all human diseases. The lead platform in development is directed at restoring protein function in diseases caused by nonsense mutations or premature termination codons (PTCs). The company was founded in 2021 by Leslie J. Williams, who has been the CEO since then. | Directeur/Membre du Conseil | 01/12/2021 |
Larkspur Biosciences, Inc.
 Larkspur Biosciences, Inc. BiotechnologyHealth Technology Larkspur Biosciences, Inc. is a company based in Watertown, MA that is pioneering a new wave in cancer therapy. Larkspur’s approach targets cancer-intrinsic factors that tumors use to escape immune detection and control to develop new treatment options for patients who cannot be helped by current therapies. The company is advancing first-in-class programs designed to eliminate tumor “bottlenecks” that drive immune evasion in colorectal cancer (CRC) and beyond. Larkx, the company’s proprietary bioinformatics platform, couples machine learning with tumor genetics to discover immune evasion pathways that originate in the tumor and enrich clinical strategies for potential responders to its therapies across multiple types of cancer. The company was founded by Nathanael S. Gray, Vijay Kumar Kuchroo, and Lewis Clayton Cantley. The CEO is Catherine Sabatos-Peyton. | Directeur/Membre du Conseil | - |
Anciens postes connus de Sacha Mann
| Sociétés | Poste | Fin |
|---|---|---|
Archangel Investors Ltd.
 Archangel Investors Ltd. Investment ManagersFinance Archangel Investors Ltd. is a Private Equity firm, a subsidiary of Riverside Global Partners LLC founded in 1988 by Michael David Rutterford and Barry Edward Sealey. The firm is headquartered in Boston. | Corporate Officer/Principal | 01/01/2009 |
Formation de Sacha Mann
| The Johns Hopkins University | Graduate Degree |
| University of British Columbia | Undergraduate Degree |
| Simon Fraser University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Takeda Ventures, Inc.
Takeda Ventures, Inc. Investment ManagersFinance Takeda Ventures Inc (Takeda Ventures) is a venture capital subsidiary of Takeda America Holdings Inc founded in 2001. The firm is headquartered in Palo Alto, California. | Finance |
Archangel Investors Ltd.
Archangel Investors Ltd. Investment ManagersFinance Archangel Investors Ltd. is a Private Equity firm, a subsidiary of Riverside Global Partners LLC founded in 1988 by Michael David Rutterford and Barry Edward Sealey. The firm is headquartered in Boston. | Finance |
Blue Mesa Health, Inc.
Blue Mesa Health, Inc. BiotechnologyHealth Technology Blue Mesa Health, Inc. engages in the provision of digital therapeutics program to support the prevention diabetes and other chronic diseases. The company was founded by Misa Nuccio, Curtis Duggan, Evan Willms, Mike Benna, Jonathan Bixby, and Joshua Bixby in 2015 and is headquartered in New York, NY. | Health Technology |
Egle Therapeutics SAS
Egle Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Egle Therapeutics SAS is a biotech company based in Paris, France. Egle Therapeutics develops first-in-class immunotherapies targeting immune suppressor regulatory T cells (Tregs) for oncology and autoimmune diseases. The French company leverages its translational-based target discovery platform to unveil novel therapeutic Treg targets and computationally designed immunocytokines acting as antagonists or as selective Treg-agonists. The company was founded in 2020 by Luc Boblet, a serial biotech entrepreneur, and Dr. Eliane Piaggio, a renowned immunologist. | Commercial Services |
Hc Bioscience, Inc.
Hc Bioscience, Inc. Pharmaceuticals: MajorHealth Technology hC Bioscience, Inc. is a biotech company based in Cambridge, MA and has subsidiaries in the United States. A single trna therapy has the potential to treat many diseases, regardless of the gene or location of the mutation. hC Bioscience is dedicated to improving the lives of patients by developing first-in-class trna-based therapeutics that target protein dysfunction. The company's innovative approach to precision protein editing has the potential to treat genetically defined conditions that account for 10-15% of all human diseases. The lead platform in development is directed at restoring protein function in diseases caused by nonsense mutations or premature termination codons (PTCs). The company was founded in 2021 by Leslie J. Williams, who has been the CEO since then. | Health Technology |
Larkspur Biosciences, Inc.
Larkspur Biosciences, Inc. BiotechnologyHealth Technology Larkspur Biosciences, Inc. is a company based in Watertown, MA that is pioneering a new wave in cancer therapy. Larkspur’s approach targets cancer-intrinsic factors that tumors use to escape immune detection and control to develop new treatment options for patients who cannot be helped by current therapies. The company is advancing first-in-class programs designed to eliminate tumor “bottlenecks” that drive immune evasion in colorectal cancer (CRC) and beyond. Larkx, the company’s proprietary bioinformatics platform, couples machine learning with tumor genetics to discover immune evasion pathways that originate in the tumor and enrich clinical strategies for potential responders to its therapies across multiple types of cancer. The company was founded by Nathanael S. Gray, Vijay Kumar Kuchroo, and Lewis Clayton Cantley. The CEO is Catherine Sabatos-Peyton. | Health Technology |
